Krilogy Financial LLC Raises Holdings in Exact Sciences Co. (NASDAQ:EXAS)

Krilogy Financial LLC raised its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 139.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 50,863 shares of the medical research company's stock after purchasing an additional 29,636 shares during the quarter. Krilogy Financial LLC's holdings in Exact Sciences were worth $2,202,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in EXAS. Capital World Investors increased its stake in shares of Exact Sciences by 10.7% during the fourth quarter. Capital World Investors now owns 17,537,617 shares of the medical research company's stock valued at $985,439,000 after buying an additional 1,696,321 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Exact Sciences by 74.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,760,241 shares of the medical research company's stock worth $323,669,000 after acquiring an additional 2,462,165 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its position in Exact Sciences by 25.8% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,269,823 shares of the medical research company's stock valued at $239,922,000 after purchasing an additional 876,985 shares during the period. Geode Capital Management LLC raised its holdings in shares of Exact Sciences by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 3,122,798 shares of the medical research company's stock valued at $175,165,000 after purchasing an additional 16,828 shares in the last quarter. Finally, Mackenzie Financial Corp raised its holdings in shares of Exact Sciences by 107.7% in the 4th quarter. Mackenzie Financial Corp now owns 2,919,325 shares of the medical research company's stock valued at $164,037,000 after purchasing an additional 1,513,873 shares in the last quarter. 88.82% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. Royal Bank of Canada lifted their price objective on shares of Exact Sciences from $52.00 to $54.00 and gave the company a "sector perform" rating in a report on Friday, May 2nd. Robert W. Baird lifted their price target on Exact Sciences from $69.00 to $72.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. William Blair restated an "outperform" rating on shares of Exact Sciences in a research note on Thursday, February 20th. Scotiabank boosted their target price on shares of Exact Sciences from $70.00 to $73.00 and gave the stock a "sector outperform" rating in a report on Monday, February 24th. Finally, Mizuho initiated coverage on shares of Exact Sciences in a research report on Thursday, April 10th. They issued an "outperform" rating and a $60.00 price objective on the stock. Two analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Exact Sciences currently has a consensus rating of "Moderate Buy" and a consensus price target of $70.90.

Exact Sciences Stock Performance

Exact Sciences stock traded down $0.49 during trading hours on Friday, hitting $53.52. 1,266,159 shares of the stock traded hands, compared to its average volume of 2,597,840. The firm's 50 day moving average price is $50.99 and its 200-day moving average price is $52.17. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.15 and a quick ratio of 1.93. The stock has a market capitalization of $10.10 billion, a price-to-earnings ratio of -9.61 and a beta of 0.98. Exact Sciences Co. has a 1 year low of $39.97 and a 1 year high of $72.83.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical research company reported ($0.21) EPS for the quarter, beating analysts' consensus estimates of ($0.37) by $0.16. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. The firm had revenue of $706.79 million for the quarter, compared to analyst estimates of $688.58 million. During the same quarter in the prior year, the firm earned ($0.60) earnings per share. Exact Sciences's revenue for the quarter was up 10.9% on a year-over-year basis. As a group, equities analysts expect that Exact Sciences Co. will post -0.58 EPS for the current fiscal year.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.